XenaCare Updates On Cobroxin Distribution
The company claims that Cobroxin is the first over-the-counter (OTC) pain reliever, clinically proven to treat moderate-to-severe (stage 2) chronic pain. Many other stage 2 drugs require prescriptions,
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.